HONG KONG – One of China’s largest chemicals producers is stepping into the biotech space via its acquisition of a hepatitis B vaccine maker. The deal comes at a sensitive time for the sector following the deaths of at least seven children blamed on those vaccines and ongoing probes into the quality of vaccine manufacturing.